Key Takeaways
- Margin expansion despite headwinds: EBITDA margin rose 150 bps YoY to 12.9% even while absorbing ~₹3.5 crores of salicylic acid losses and low initial utilization at the newly commissioned Sayakha plant.
- Export volumes rescued a soft domestic quarter: Export API volume grew over 30%, offsetting flat-to-slightly-negative domestic demand and driving overall API volume growth of 9.33%.
- Sayakha plant is live but early: The new methylamine facility began commercial production on September 4, 2025, and currently meets roughly 40% of captive consumption; management expects 18–20% EBITDA margins from the project at scale.
- Salicylic acid is the margin unlock story: The Tarapur plant achieved required purity in September 2025 and is now widely accepted in the market; the plant turns EBITDA positive above ~800 tons/month, with 300 tons/month achievable near-term and 500 targeted by Q4 FY26.
- What to watch next quarter: Whether salicylic acid volumes ramp on schedule, the pace of Sayakha utilization improvement beyond 40% captive coverage, and any sign of the promised Q4 domestic demand pickup.
Margin Walk: Headwinds Absorbed, Recovery Promised
- Gross margin reset, not efficiency gain: The 300+ bps gross margin improvement reflects stabilization of raw material prices after the post-Russia-war oil spike, not operational efficiencies. Under FIFO accounting, the prior declining-price environment had artificially compressed margins; now that volatility has subsided, true margins are emerging.
- Two active drags: The company absorbed ~₹3.5 crores of losses in the salicylic acid chain and carried low initial capacity utilization expenses from the Sayakha plant, which operated for only one month of the quarter.
- Sequential improvement expected: Management expects quarter-on-quarter margin increases as salicylic acid scales and Sayakha utilization rises, with an ultimate target of 15–16% consolidated EBITDA margin.
- Tax rate normalizing: The low Q1 tax rate reflected prior-year refunds; more refunds are expected in Q3/Q4, but the normalized rate for the next three years including FY27 should be around 25%.
Adhish Patil: "we are quite confident that once we get all these things in order, on a quarter-on-quarter basis, sequentially, our margins should steadily keep on increasing, and our ultimate target should be somewhere between 15% to 16%."
Sayakha: The Anti-Diabetic Backward-Integration Bet
- What the plant makes: Dimethylamine, Monomethylamine, Trimethylamine and their derivatives, key intermediates for anti-diabetic products including Metformin. Total capacity is 60 TPD, scalable to 80 TPD.
- Current status: Commercial production began September 4, 2025; quality was spot-on from day one. The plant currently satisfies roughly 40% of captive consumption, with management trying to ramp up quickly once equipment-related issues are resolved.
- Ramp-up timeline: Expected to scale to fulfill entire captive requirement over the next 6–12 months, with full utilization targeted by end of FY26. Export market entry will follow as volumes scale.
- Project economics: Management expects around 18–20% EBITDA margins from the project, though it declined to quantify the exact bps benefit to consolidated margins at full capacity, citing uncertainty about how conditions will evolve.
- Competitive positioning: The project is not import-substitution but competes with domestic manufacturers.
- Downstream expansion: Planning to expand Metformin capacity going forward, with similar CAPEX of around ₹200 crores likely required in FY27.
Salicylic Acid: The Margin-Unlock Story
- Quality milestone achieved: The Tarapur facility reached the required purity profile in September 2025, roughly two months before the call. The product is now widely accepted and sold to the majority of salicylic acid customers in India.
- Volume ramp plan: 300 tons per month is achievable near-term; the target is 500 tons per month by Q4 FY26. The plant turns EBITDA positive once it crosses approximately 800 tons per month.
- Downstream integration: The salicylic acid output will supply an upcoming 400 tons per month downstream line, enabling further integration.
- Growth dependency: Management flagged salicylic acid ramp-up as the key challenge to achieving its 15–20% FY27 growth aspiration, requiring at least 60% utilization.
Demand Environment: Exports Strong, Domestic Waiting
- Export volume surge: Export API volume grew over 30% in Q2, the primary driver of the quarter's 9% YoY revenue growth and 9.33% API volume growth.
- Domestic weakness concentrated in antibiotics: Domestic API volume was flat with slight de-growth of ~2%, driven by lackluster demand in the antibiotic therapy category.
- Q3 expected lean, Q4 the hope: Management noted Q3 is typically a lean quarter for acute therapy and hopes for a slight pickup in domestic demand from Q4 onward, though it will take two to three months to assess.
- API pricing stabilizing: Early signs of stability in global API pricing are expected to support volume growth and price recovery in H2 FY26.
Adhish Patil: "Q3 is typically a lean quarter anyways for the acute therapy. So, we hope that from Q4 onwards, there should be some slight pickup in the domestic demand. But we will come to know within two to three months."
Regulatory & Market Access Pipeline
- EU certifications in process: The company is working to receive EU certifications for several key products from large-scale plants, which would allow shipment of EU-registered products from lower-cost facilities and expand export margins.
- US market entry beginning now: Bicalutamide will be the first product commercialized in the US, expected this quarter. Metformin is targeted for the US market post-FY26 once ongoing validation processes are completed.
- Regulated markets beyond the US: A few anti-diabetic products are expected to commercialize in Europe, the UK and other regulated markets (ex-US) within the next six to nine months.
- Revenue contribution: These new product launches combined should add an additional ₹60–70 crores to the top line.
- Longer pipeline: A product portfolio for the next 5–10 years is under development, focusing on derivatives of the two main Greenfield projects; GLP-1 molecules will be evaluated as part of this exercise based on the company's strengths, weaknesses, and client profile.
Adhish Patil: "we are forming a product portfolio. We will consider these molecules as well, what you mentioned right now, into account and looking at our strengths and weaknesses and kind of markets, kind of client profile this certain molecule has and whether we are already dealing with those clients, based on all these factors, we will narrow down the list and start working towards that goal."
Balance Sheet & Capital Allocation
- Debt reduction continues: Total debt reduced by ₹41 crores to ₹571 crores, producing a record low debt-to-equity ratio of 0.39 and lower finance costs. The target range for debt-to-equity is 0.4 to 0.7.
- FY26 CAPEX: Estimated at ₹150–200 crores of investing cash flows.
- FY27 CAPEX: A similar ~₹200 crores may be required for Metformin expansion.
- Longer-term CAPEX: Further plans will be announced once the 5–10 year product portfolio blueprint is finalized.
- Other income: Expected to be steady for the full year, though it may shift between quarters; management declined to provide specific H2 guidance.
- Operational incident contained: A voluntary closure direction was received from the Maharashtra Pollution Control Board for the chlorosulfonation process at Tarapur T-150 following an isolated HCL gas leakage on September 8, 2025. There were no injuries or casualties; the closure was precautionary with no material financial or operational impact due to adequate inventory and alternate sourcing. All other Tarapur processes continue normally.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Sayakha captive utilization | Achieve 100% captive consumption for anti-diabetic series | End of FY26 |
| Sayakha ramp-up | Scale to fulfill entire captive requirement | Next 6–12 months |
| Salicylic acid volume | Ramp to 500 tons per month | Q4 FY26 |
| Salicylic acid breakeven | Turn EBITDA positive above ~800 tons/month | Not specified; volume-dependent |
| US market entry | Commercialize Bicalutamide (first US product) | Current quarter (Q3 FY26) |
| Regulated market launches (ex-US) | Commercialize a few anti-diabetic products in Europe, UK, and other regulated markets | Next 6–9 months |
| New product revenue | Additional ₹60–70 crores top line from new launches combined | Not specified; tied to launch timelines |
| H2 FY26 revenue growth | High single-digit value growth | H2 FY26 |
| FY27 revenue growth | 15–20% growth, conditional on salicylic acid ramp-up | FY27 |
| FY27 margin target | Hit 15% EBITDA margin run rate toward end of FY27 | H2 FY27 or later |
| FY26 CAPEX | ₹150–200 crores investing cash flows | FY26 |
| FY27 CAPEX | ~₹200 crores for Metformin expansion | FY27 |
| Debt-to-equity range | Maintain between 0.4 and 0.7 | Ongoing |
| Tax rate | Normalized rate around 25% | Next three years including FY27 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated revenue | ₹652.9 cr, +9% YoY |
| Consolidated EBITDA | ₹84.4 cr, +23% YoY |
| Consolidated EBITDA margin | 12.9%, +150 bps YoY |
| Consolidated PAT | ₹45.2 cr, +29% YoY |
| Consolidated PAT margin | 6.9%, +110 bps YoY |
| Standalone revenue | ₹578.9 cr, +7% YoY; 89% of consolidated revenue |
| Standalone EBITDA margin | ~13%, slightly crossed 13% |
| Formulation segment revenue | ₹82.4 cr, +26% YoY; exports contributed 68% |
| API segment volume growth | 9.33% overall; domestic flat with slight de-growth, exports +30% |
| CAPEX incurred during the quarter | ₹45.6 cr |
| Total debt (consolidated) | ₹571 cr, reduced by ₹41 cr during H1 FY26; debt-to-equity ratio 0.39 |
| Salicylic acid plant production target | 300 tons/month near-term, ramping to 500 tons/month by Q4 FY26 |
| Salicylic acid plant EBITDA breakeven | Expected at ~800 tons/month |
| Methylamine plant capacity | 60 TPD, scalable to 80 TPD |
| Metformin capacity | 1,400 metric tons/month |
| Tax rate guidance | ~25% for FY26 and FY27 |
| H2 FY26 value growth target | High single digit |